We use cookies to study and improve the user experience offered by the site. By continuing to browse the site you are agreeing to our cookie policy.

Polycythemia vera

The information provided on www.fcarreras.org pretend to support, not replace, the relationship between patients/visitors of this website and their doctor.

What is polycythemia vera and whom does it affect?

Polycythemia vera (PV) is a malignant disease, one of the chronic myeloproliferative syndromes (CMPS), or myeloproliferative neoplasms. These diseases have a common characteristic, the stem cells in the bone marrow, responsible for producing all the blood cells, have a defect which makes them produce one of the myeloid lineage blood cells in an uncontrolled manner.

In the case of polycythemia vera, due to a mutation in a cell that produces the red blood cells, the blood becomes thicker on account of a considerable increase in the number of red blood cells.

In our country the incidence of polycythemia vera is 4-6 cases per million, per year. The average age at diagnosis is 60. This disease is rare before the age of 40.

Symptoms and diagnosis

In the majority of cases the disease does not present any symptoms and is generally diagnosed as a result of a routine blood test. If there are any clinical manifestations they can include: non-specific symptoms (50%) (asthenia, night sweats, weight loss, attacks of gout, epigastric pain, generalised pruritus [itch]); thrombotic phenomena (50%) (stroke, angina, infarction, intermittent claudication of the lower limbs and abdominal venous thrombosis [portal, splenic, hepatic]); peripheral venous insufficiency (reddening and pain/burning sensation in the fingers and soles of the feet, which is accentuated with heat, such as taking a shower, and ameliorated when exposed to cold). Hemorrhages (nose bleeds, bleeding gums, gastrointestinal bleeding) are not infrequent (15-30%), nor are neurological manifestations (60%) (migraine, tingling sensation in the hands and feet, dizziness, visual alterations).

Three measurements of red blood cell concentrations may be used to diagnose polycythemia vera: the hematocrit level (greater than 51% in men and 48% in women), the concentration of hemoglobin (greater than 185 g/l in men and 165 g/l in women) and a red blood cell count (values greater than 5-6 million). These measurements form part of a standard blood test, a hemogram blood test, and if PV is suspected, it is relatively simple to confirm so and, furthermore, the test frequently demonstrates an increase in the values for white blood cells (leucocytosis) and platelets (thrombocytosis).

To complete the study and establish the definitive diagnosis there must also be, at least, a molecular study (to detect the presence of a specific mutation of the JAK2 gene), a bone marrow biopsy, and a quantification of serum erythropoietin concentration (always low).

Treatment

Treatment for PV must be based on bloodletting, acetylsalicylic acid (aspirin), and hydroxyurea or radioactive phosphorus.

Bloodletting is the treatment of choice in most cases for patients with a history of thrombosis. It is performed every three or four days and 400 ml of blood is extracted to reduce the hematocrit level (up to 45% for men and 42% for women). The procedure includes regular monitoring of the patient.

For patients with a risk of thrombosis, the treatment of choice is with hydroxyurea, although, with patients of advanced age the use of radioactive phosphorus is preferred.

Unless contraindicated, all patients must take 100 mg of aspirin per day. Many patients also require allopurinol to reduce the values for uric acid.

For patients with marked thrombocytosis the administration of anagrelide may be indicated.

Prognosis

Although it is not a curable disease, it is, because of its chronic nature, usually effectively managed over long periods of time. Nevertheless, an increase in the number of red blood cells and platelets can lead to the hemorrhagic/thrombotic complications mentioned earlier. Over years patients with PV may evolve to myelofibrosis with bone marrow exhaustion (deficit of all the normal elements of the blood). Similarly, and especially after many years of treatment with hydroxyurea, there may be an evolution to acute myeloblastic leukaemia.

In spite of all this, well treated patients have an average expectation of survival that exceeds 15 years.

Links of interest concerning medical issues relating to polycythemia vera

For more quality information about polycythemia vera, you can consult the following websites:

 

Links of interest about other general issues that may be of interest for patients with polycythemia vera

There are other resources and links (in Spanish) of interest that may be of use to polycythemia vera patients

Help and support

If you are suffering from leukaemia you can access the Josep Carreras Foundation's patients' and former patients' forum a group of people who support each other to help live through this situation in the best possible way. You can access the forum here.

On our website you will also find the testimonies of people who are suffering, or who have suffered, from this disease. We would also like to invite you to follow us on our main social networks (FacebookTwitter e Instagram) where we often share patients' accounts of overcoming the disease.

If you are resident in Spain, you can also contact us via email [email protected] so that we can help put you in contact with other patients who have overcome this disease.

You will find many other topics of interest about diet, fertility, treatments, etc., on our BLOG 'Unstoppable against leukaemia'.

Webpage updated 07/17/2020 10:41:35